Akamis Bio key facts
as of Oct 2026- Operator of a clinical-stage oncology company intended to develop cancer gene therapies.
- Akamis Bio is valued at approximately $145.3M as of Oct 2026 (last reported valuation).
- It has raised $184.6M; the latest was Later Stage VC ($60.0M) in Dec 2024.
- Notable investors include Salica Investments, ARCH Venture Partners, Bristol-Myers Squibb, Revelation Partners, SR One Capital Management — 25 tracked in total.
- Status: Privately Held (backing).
Akamis Bio's last reported valuation, Jan 2023. Nothing priced has surfaced since.
- ·The complete investor list: 25 names
- ·Watch Akamis Bio: the Monday email on marks, rounds and moves
Akamis Bio funding rounds
No funding rounds for Akamis Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Akamis Bio
25+Akamis Bio valuation
Akamis Bio's last reported valuation was $145 million in Jan 2023. No priced round, secondary trade or fund mark has surfaced since.
Akamis Bio investors
25 investors are on record for Akamis Bio, including Salica Investments, ARCH Venture Partners, Bristol-Myers Squibb and Revelation Partners. By type, the record holds 5 venture capital firms and 1 asset manager.
About Akamis Bio
Operator of a clinical-stage oncology company intended to develop cancer gene therapies. The company focuses on immunobiology treatments for solid tumors using the proprietary intravenously administered T-SIGn virus platform, enabling patients to get proper treatment who are suffering from cancer.
- Sector
- Healthcare
- HQ
- Abingdon, United Kingdom
- Founded
- 2006
- Employees
- 34
- Website
- akamisbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.